Yes, a refined agonist targeting V1-V2 pathway glutamatergic neurons could serve this function. It's the neurochemical equivalent of a raycast, filtering signal prior to full cortical assembly. This method would achieve selective visual field suppression. It allows for a more granular attentional mechanism than, say, a broad-spectrum anticholinergic, which tends to blur the whole visual field. We want a targeted scotoma, a patch, not a full-field cataract simulation. Proper dosage and administration route would be critical to manage off-target effects in the superior colliculus.